WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today thanked Congress and the President for working together to pass the latest COVID-19 stimulus package, which will provide additional relief for smaller medical technology companies and a significant boost to the nation’s testing capabilities.
WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker released the following statement:
WASHINGTON, D.C. – Several prominent medical technology company executives have been named to the White House task force designated by President Trump to provide recommendations on how best to safely reopen the U.S. economy in the wake of the coronavirus (COVID-19) pandemic.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today released the following statement from President and CEO Scott Whitaker on STERIS’s Emergency Use Authorization (EUA) from FDA for certain V-PRO® Low Temperature Sterilization Systems to allow health care providers to decontaminate N95 respirators on site:
WASHINGTON – New clinical evidence produced in recent weeks has shown the benefits of non-invasive ventilators for use in less severe cases of COVID-19-related respiratory problems, which constitute the majority of cases nationwide. In a series of white papers, published evidence, and case studies from both China and Italy, experts say many coronavirus patients with less-severe respiratory distress could benefit from non-invasive ventilation therapy, thus freeing more invasive ventilation devices for the most critically ill patients nationwide.
WASHINGTON, D.C. – An editorial authored by Andrew Fish, Chief Strategy Officer for The Advanced Medical Technology Association (AdvaMed), appeared this week in Real Clear Health on the benefits of telehealth in connecting patients and health care providers, particularly during the current coronavirus (COVID-19) health care crisis.
WASHINGTON, D.C. – President and CEO of AdvaMed Scott Whitaker released the following statement:
“Given recent allegations of price gouging in some parts of the country, it is important to be perfectly clear:
“Our member companies’ No. 1 priority is saving lives and at no time in our history has that been more apparent than over the past month as they have dramatically ramped up production of the diagnostics and devices that are essential to identifying, treating and combatting COVID-19.
WASHINGTON, D.C. – The Advanced Medical Technology Association announced today that its member respiratory device companies have dramatically expanded the limits of their present production capacity in responding to the coronavirus outbreak, producing on average 2,000-3,000 ventilators per week, collectively, according to a recent survey of the seven member companies. In the coming weeks, company officials expect to ramp production to unprecedented levels, producing between an aggregated 5,000 and 7,000 ventilators per week in meeting the greatest needs across the nation. In 2019, when tallied together, these same companies were manufacturing approximately 700 ventilators per week for domestic distribution.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today released the following statements by Scott Whitaker, AdvaMed president and CEO, and Susan Van Meter, executive director of AdvaMedDx, regarding the medtech industry’s ongoing response to the coronavirus pandemic:
WASHINGTON, D.C. – Today, AdvaMed President and CEO Scott Whitaker released a statement applauding congressional passage of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.